Research Advances in Cancer Nanomedicine
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 1 April 2025 | Viewed by 91
Special Issue Editor
Interests: nanomedicine; drug delivery; scanning force microscopy; cytomechanics; nanocarriers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is considered the evil of the Century, since it is the main cause of millions of deaths for the human species. Several issues related to heterogeneities of tumors, multidrug resistance and genetic factors are among major factors faced by (most of) targeted therapies and early diagnoses recently developed in cancer medicine. Cancer Nanomedicine, that is Nanotechnology applied to Cancer Theragnostic (e.g. Therapy plus Diagnosis) could shed a new starlight into the darkness of Neoplasia world. In this respect, several type of nanocarriers (“nanometric” entities like nanoparticles)-bringing reduced concentrations of antineoplastic drugs in their interior- can be driven to a target tumor by “Targeted Nano-Drug Delivery”, reducing unwanted side effects from therapeutic side, and on the other hand Lab-on-Chip Technologies have been also developed, being able to detect and quantify infinitesimal concentration of cancer biomarkers in order to enhance\speed up diagnosis, thus avoiding unpleasant biopsies. With this idea in mind, this Special issue is thought to bring together recent progresses and developments in the area of nanomedicine devoted to cancer therapy and diagnosis. For example, CAR-T Nano-technology and Nano-immunotherapy are among novel areas, attracting important financial resources and increasing interests in the stakeholders.
Prof. Dr. Stefano Leporatti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- nanotechnology
- nanomedicine
- drug delivery
- biosensors
- lab-on-chip
- nanomechanics
- nano-immuno therapy
- CAR-T nano-technology
